Sugi Predict

Sugi Predict / Compounds / SCHEMBL2985133

SCHEMBL2985133

SCHEMBL2985133

CC1(C)C(=O)NC(=O)N1CCNc1ncc(Cl)c(-c2nnc(Nc3ccccc3)s2)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MARK3 P27448 1/20 0.36
▸ ALK Q9UM73 2/20 0.35
▸ CDK19 Q9BWU1 1/20 0.35
▸ USP2 O75604 3/20 0.34
▸ CYP1A2 P05177 3/20 0.34
▸ CASP7 P55210 2/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ WEE1 P30291 6/20 0.34
▸ EGFR P00533 2/20 0.34
▸ FGFR1 P11362 2/20 0.34
▸ SRC P12931 1/20 0.34
▸ FGFR2 P21802 1/20 0.34
▸ FGFR4 P22455 1/20 0.34
▸ FGFR3 P22607 1/20 0.34
▸ CCND3 P30281 2/20 0.33
▸ CCNK O75909 1/20 0.33
▸ CDK9 P50750 1/20 0.33
▸ CDK6 Q00534 1/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ CYP2C19 P33261 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2978356 0.90 GUSB (0.39) USP2CYP1A2CASP7ALDH1A1EGFR
SCHEMBL2979553 0.85 FGFR1 (0.34) USP2CYP1A2CASP7ALDH1A1EGFR
SCHEMBL2986223 0.81 FGFR1 (0.35) EGFRFGFR1CCND3CDK9GSK3B
SCHEMBL2983794 0.78 MEN1 (0.31) USP2CYP1A2CASP7ALDH1A1MEN1
SCHEMBL13685006 0.77 LRRK2 (0.36) CCND3CCNKCDK9CDK6LRRK2
SCHEMBL2976762 0.74 ADORA1 (0.41) USP2CYP1A2CASP7ALDH1A1EGFR
SCHEMBL2988264 0.73 PDE7A (0.43) USP2CYP1A2CASP7ALDH1A1MEN1
SCHEMBL2988266 0.73 PDE7A (0.43) USP2CYP1A2CASP7ALDH1A1MEN1
SCHEMBL2980841 0.72 ADORA1 (0.40) MARK3USP2CYP1A2CASP7ALDH1A1
SCHEMBL2976992 0.72 DRD2 (0.32) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1831207-B1 AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS AMGEN INC (US) 2012-11-14 — — EP disclosed
US-7858785-B2 Aminopyrimidine compounds and methods of use AMGEN INC. (US) 2010-12-28 — — US disclosed
US-7786132-B2 Aminopyrimidine compounds and methods of use AMGEN INC. (US) 2010-08-31 — — US disclosed
US-20100010014-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2010-01-14 — — US disclosed
EP-1831207-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2007-09-12 — — EP disclosed
US-20070185133-A1 Aminopyrimidine compounds and methods of use AMGEN, INC. (US) 2007-08-09 — — US disclosed
WO-2006066172-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE AMGEN, INC. (US) 2006-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010014-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE PLK1, TYMP, TK2 MARK3 919/4885ALK 3069/4885CDK19 100/4885
US-20070185133-A1 Aminopyrimidine compounds and methods of use PLK1, TYMP, TK2 MARK3 919/4885ALK 3069/4885CDK19 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.